Zacks Investment Research Lowers Monopar Therapeutics (NASDAQ:MNPR) to Sell

Zacks Investment Research downgraded shares of Monopar Therapeutics (NASDAQ:MNPR) from a hold rating to a sell rating in a research note released on Wednesday, Zacks.com reports.

According to Zacks, “Monopar Therapeutics Inc. is a biopharmaceutical company. It is focused on developing drugs for cancer patients. The company’s intellectual property pipeline consists of Validive(R), Camsirubicin (MNPR-201) and MNPR-101 which are in clinical stage. Monopar Therapeutics Inc. is based in Wilmette, United States. “

Separately, HC Wainwright began coverage on Monopar Therapeutics in a report on Monday, November 1st. They issued a buy rating and a $9.00 price target on the stock.

NASDAQ MNPR opened at $2.96 on Wednesday. Monopar Therapeutics has a 1 year low of $2.76 and a 1 year high of $17.01. The business’s fifty day moving average is $4.00 and its two-hundred day moving average is $4.71.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings results on Friday, November 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.02. As a group, analysts anticipate that Monopar Therapeutics will post -0.7 EPS for the current year.

An institutional investor recently raised its position in Monopar Therapeutics stock. Vanguard Group Inc. boosted its position in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) by 116.2% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 97,462 shares of the company’s stock after purchasing an additional 52,392 shares during the period. Vanguard Group Inc. owned 0.78% of Monopar Therapeutics worth $574,000 at the end of the most recent reporting period. 1.57% of the stock is owned by institutional investors and hedge funds.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart, which is in Phase 2 clinical trial; and MNPR-101, a humanized monoclonal antibody for the treatment of advanced cancers and severe COVID-19 that is in preclinical stage.

Recommended Story: Outstanding Shares

Get a free copy of the Zacks research report on Monopar Therapeutics (MNPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.